Inhibitors | Comment | Organism | Structure |
---|---|---|---|
gamma-tocotrienol | a component of vitamin E, gammaTE, inhibits DEGS and decreases de novo ceramide synthesis, elevation of ceramides during prolonged gammaTE treatment is likely caused by sphingomeylinase-mediated hydrolysis of sphingomyelin | Homo sapiens |
Organism | UniProt | Comment | Textmining |
---|---|---|---|
Homo sapiens | O15121 | - |
- |
Source Tissue | Comment | Organism | Textmining |
---|---|---|---|
HCT-116 cell | - |
Homo sapiens | - |
MCF-7 cell | - |
Homo sapiens | - |
PANC-1 cell | - |
Homo sapiens | - |
Synonyms | Comment | Organism |
---|---|---|
DegS | - |
Homo sapiens |
dihydroceramide desaturase | - |
Homo sapiens |
Temperature Optimum [°C] | Temperature Optimum Maximum [°C] | Comment | Organism |
---|---|---|---|
37 | - |
assay at | Homo sapiens |
pH Optimum Minimum | pH Optimum Maximum | Comment | Organism |
---|---|---|---|
7.4 | - |
assay at | Homo sapiens |
General Information | Comment | Organism |
---|---|---|
malfunction | gamma-tocotrienol inhibits cellular dihydroceramide desaturase (DEGS) activity without affecting its protein expression or de novo synthesis of sphingolipids. Unlike the effect on dihydroceramides, gamma-tocotrienol decreases ceramides (Cers) after 8-h treatment but increases C18:0-Cer and C16:0-Cer after 16 and 24 h, respectively. The increase of ceramides coincides with gamma-tocotrienol-induced apoptosis and autophagy. Since gamma-tocotrienol inhibits DEGS and decreases de novo ceramide synthesis, elevation of ceramides during prolonged gamma-tocotrienol treatment is likely caused by sphingomeylinase-mediated hydrolysis of sphingomyelin. gamma-Tocotrienol treatment led to a time- and dose-dependent decrease in viability of colon, pancreatic and breast cancer cells, overview | Homo sapiens |